Citius Pharmaceuticals Inc (CTXR) 뉴스

ctcx.....................https://stockcharts.com/h-sc/ui?s=ctcx&p=W&b=5&g=0&id=p86431144783

CTXR $4.20

CTXR

$3.47 + 8% CTOR side running ok

CTXR................................https://stockcharts.com/h-sc/ui?s=CTXR&p=W&b=5&g=0&id=p86431144783

CTXR.............................https://stockcharts.com/h-sc/ui?s=CTXR&p=D&yr=0&mn=2&dy=12&id=p84071410134

ctxr.........thx.....

https://x.com/CripToz5/status/1861037191272563119

CTXR..........................https://stockcharts.com/h-sc/ui?s=CTXR&p=W&b=5&g=0&id=p86431144783

Will they do a R/S before Dec 3rd?

Because if they don't, they will be delisted from NQ. The standard stalling technique of requesting an extension and then requesting a hearing before the Nasdaq Hearing Panel has happened. There are no more ways to stave off delisting other than a R/S. On November 6, 2024, the Company received a decision letter from the Panel granting the Company’s request to continue its listing on The Nasdaq Capital Market, subject to regaining compliance with the Bid Price Rule on or before December 3, 2024.

Time to get on board...train is about to leave you behind!!!!

Some information from today's conference: CTXR and CTOR information: TwongStocks recap:

https://www.reddit.com/r/CTXR/comments/1gfn9qe/thinkequity_conference_recap_with_audio_link/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button

If you have heard previous conferences, you've basically heard this one. Essentially followed the same script. Did not cover compliance or cash runway.

He did give a bit of info regarding the distribution of CTOR shares. I believe this is the first time he has verbalized the 6 month lockup. While that was stated in the SEC filings, this is the first I recall Leonard ever mentioning the lockup in a conference.

Our plan is to ultimately distribute the shares or dividend the shares to the Citius Pharma shareholders. We couldn't do that right away because we had a lockup on the shares for six months. So we got to wait until that lockup is over and then we'll start making the moves on doing the distribution.

He reiterated that during the summary at the end of the conference

And as I said before, our plan with Citius Oncology is to dividend and distribute those shares once that lockup period is over, which will provide a benefit in participation for the Citius shareholders.

There was a Q&A at the end. Unfortunately, the questions were only from the audience participants and couldn't be heard.

His first answer:

Yes, there is a specific date. It's in the third week.

Since I couldn't hear the question, no idea what this is referring to. My guess is that it is referencing the FDA meeting in November.

Second question was about the distribution of CTOR shares, based on his answer:

Do we have a what? No, not yet. Because we're waiting until the six month period is up, which will be in February and somewhere after that, we want to see what market conditions look like. We want to be careful how we do this. So it doesn't cause any negative pressure on Citius Pharma in the process r the other company as well. So we have to distribute this very, very carefully. It's got to look at market conditions when we're doing it.

I could tell you when I was at Cooper Labs, we did this. We spun off, it became CooperVision from CooperLabs. And we actually waited a whole year before we distributed those shares. And it was successful. And the reason it was successful for both companies is, and why it'll be successful for us, is because CooperVision was growing like a rocket at that time. And we anticipate we're gonna have good growth here. We think that within the first year, we'll have positive earnings for, uh, for this business. So that's the best time to, to really do a dividend distribution of shares.

Couple things about the potential distro.

They won't distribute until sometime after the lockup is over. Lockup expires in Feb, 6 months after the spinoff closed.

The distribution will be done very carefully and based on market conditions. Last thing they want to do is tank the stock.

They've mentioned that they'll be able to report CTOR's financials and revenues on CTXR's consolidated balance sheet, since CTXR owns 92% of CTOR. However, if they do a full distribution before the end of Q1 2025, they won't be able to do that. Once CTXR ceases to own more than 50% of CTOR, CTXR won't be able to report CTOR's financials on their consolidated financials. So it will be interesting to see the timing and how they plan to dividend those shares. If Lymphir is being launched in January and all of the shares are distributed in February, CTXR will never get the "benefit" of being able to report CTOR revenues.

Accumulating down here

Could this be the beginning of our share price upswing? Lots of analysts think $6 price as a 12 month target.

CTXR 10Q due AUGUST19

TENK has a t12 halt…. Not good

BLA approval EXPECTED (NOT GUARANTEED) in 5 business days or less.

The buying continues for CTXR. Pre maket this morning currently has the stock price up another 4% @ $1.06.

July 3rd 2024 it closed @ .485.

Today..Since..,multi$'price target-recentPR.news set..sudden-up.trend.as.if some.know

CTXR new 52 week low

At last some good news on the catheter treatment,....

https://finance.yahoo.com/news/citius-pharmaceuticals-achieves-primary-secondary-110000306.html

https://www.sec.gov/Archives/edgar/data/1506251/000121390024022184/ea0201715-8k_citius.htm

This was released on 2/14/2024, and the BLA was filed on 2/13/2024 with the FDA.

So if CTXR is correct CTXR should receive an answer within the next 2 weeks.

As of now, the 9:16am Pre market is looking good. Just have to wait and see if the normal trading hours follow through.

"FDA acceptance of the completed resubmission package and issuance of a Prescription Drug User Fee Act (PDUFA) date is expected within 30 days of resubmission."

https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Resubmits-the-Biologics-License-Application-of-LYMPHIR-Denileukin-Diftitox-for-the-Treatment-of-Adults-with-Relapsed-or-Refractory-Cutaneous-T-Cell-Lymphoma/default.aspx

Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
02/14/2024

FDA acceptance of the completed resubmission package and issuance of a Prescription Drug User Fee Act (PDUFA) date is expected within 30 days of resubmission

Link:
https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Resubmits-the-Biologics-License-Application-of-LYMPHIR-Denileukin-Diftitox-for-the-Treatment-of-Adults-with-Relapsed-or-Refractory-Cutaneous-T-Cell-Lymphoma/default.aspx

Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors
January 23, 2024

"This is a pivotal time for Citius as it prepares to transition from a clinical-stage company to a commercial organization"

https://citiuspharma.com/investors/news-media/news/release-details/2024/Citius-Pharmaceuticals-Announces-Nomination-of-Pharmaceutical-Executive-Robert-J.-Smith-to-its-Board-of-Directors/default.aspx

https://www.otcmarkets.com/stock/CTXR

The shareholders will receive shares in the new company(see below).



"As previously announced, the Company is in the process of formulating a plan of distribution of a portion of the shares of Citius Oncology to its shareholders."


The wording is in the paragraph labeled(see link below) :

"CITIUS PHARMA AND TENX COMMENTS"

LINK:
citiuspharma.com/investors/...


Also, if CTXR owns 90% of the stock of the new company means they will pick up an unrealized gain if the price of the new company goes up since CTXR will carry the 90% as an investment and adjust the value to reflect the price also benefiting the stock price of CTXR and the stockholders will benefit also.

It's a win win.

So basically if they make a spinoff company, it hurts CTXR investors big time because they wont see the benefit.

https://www.otcmarkets.com/stock/CTXR

Notice they said that the agreement had to be ratified by TenX but they didn't say anything about the CTXR investors having to vote on this. How could that be?

I am guessing the reason CTXR shareholders do not have to approve it is because CTXR is the only shareholder of the spin off company and the Board approved it: ( see below).

"the approval and adoption of the Merger Agreement and the transactions contemplated
thereby by the requisite vote of TenX’s shareholders (the “Parent Shareholder Approval”) and the requisite approval of Citius Pharma, as SpinCo’s sole shareholder."

Wow! What just happened? I think CTXR just bought itself for $750M. Given that it had only a $107M market cap, I think that is a pretty neat trick. Actually, it bought 90% of itself for $675M. What happened to the other 10%. Is this just a 10% dilution, or is this a 10% dilution where somebody gets skewered by a factor of (750/107 )/.9 = 7.8X. Now who would that be that would get skewered (if anyone)? CTXR is held; 7.8% by Insiders, 10.7% by Institutions, so I assume about 81.5% by Retail Investors. Must be the Institutional Investors and Insiders that are getting skewered if anyone... right? That is how this works, right? SPAC's are used by non-public companies that want to go public. This time it is a public company changing it's name. New use of an SPAC? Changing it's name and probably f%$&g you in the a%##. Deep down you can feel it, can't you? Notice they said that the agreement had to be ratified by TenX but they didn't say anything about the CTXR investors having to vote on this. How could that be? Ouch! Deeper! Cut that out! You should have known that something was fishy when the 100% efficacious Mino-Lok trial that should have ended a very long time ago went silent for so long. You have to wonder if the BLA submission issues were deliberate to tank the price and give time to set this (skewering?) up. As a wealthy manager once said to me after I invented something valuable for the company and then asked for a promotion, "You (retail investors) are used to not having any money. You don't need money". They on the other hand are very very rich, so they need your money more than you need it. It's all good.

https://www.otcmarkets.com/stock/CTXR

CTXR new 52 week low

CTXR new 52 week low

CTXR
Citius Pharmaceuticals Inc
0.955
-0.0414 (-4.15%)
Volume: 1,010,947
Day Range: 0.9384 - 1.00
Last Trade Time: 7:48:52 PM EDT

Wow still alive

CTXR Latest News Citius Pharmaceuticals to be Added to Russell 3000® and Russell 2000® Indexes 06/26/2023 08:30:00 AM
Current Report Filing (8-k) 06/20/2023 04:06:30 PM

$CTXR Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids 06/20/2023 08:30:00 AM

$CTXR Citius Pharmaceuticals to Participate in Maxim Group's Virtual Healthcare Conference on June 21, 2023 06/13/2023 08:30:00 AM

$CTXR Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update 05/12/2023 04:30:00 PM

CTXR
Citius Pharmaceuticals Inc
1.17
-0.04 (-3.31%)
Volume: 627,282
Day Range: 1.18 - 1.24
Last Trade Time: 7:50:58 PM EDT

Thank you. That explains it. Have my fingers crossed for a positive summer. I'm retiring next Friday, and it would be a nice safety net.
:)

That was shares that were bought for the inclusion in the Russell index that was effective after the close today.

It was expected.

Today is the 4th Friday.

Every year on the fourth Friday of June, the Russell 1000, Russell 2000, Russell 3000 and other Russell indexes are reconstituted. FTSE Russell gives investors a heads up about what moves they should expect.

What's up with the $10+ million share purchase at close?

Well - they have said that was their goal, and that it was 'supposed' to happen sometime during 2023. It would appear that things are moving forward.

New spinoff company??

https://www.bizapedia.com/nj/citius-oncology-inc.html

Ther Vs ctxr

Ther good news on cancer csn jump back to 52 week high

https://www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html

best guess is that a large holder sold a chunk a couple of days ago, driving price down after a moderate run, and now a good number of folks are getting on board, seeing potential success coming a bit closer.

Interesting trading day here today. I can't find any new news - so I am not sure what's driving things.

A bit of news - Citius extends gains on advancing efforts to spin off oncology asset

https://seekingalpha.com/news/3952716-citius-stock-gains-on-spin-off-plans-for-oncology-asset

Mar. 30, 2023 9:29 AM ET
Citius Pharmaceuticals, Inc. (CTXR)
RDY
By: Dulan Lokuwithana, SA News Editor

After a 7% rise in the previous session, Citius Pharma (NASDAQ:CTXR) shares continued to gain in the pre-market Thursday after the company highlighted progress on its previously announced plans to spin off oncology candidate I/ONTAK into a standalone publicly-traded entity.

In a press release on Thursday, Citius (CTXR) said that in connection with the transaction, it has selected Maxim Group LLC as the financial advisor to its wholly-owned subsidiary, Citius Acquisition Corp.

Following the spinoff, Citius (CTXR) is expected to continue to trade on the Nasdaq under its current ticker CTXR.
I/ONTAK is a reformulation of the previously FDA-approved oncology treatment ONTAK which was available in the U.S. market from 1999 – 2014 but voluntarily withdrawn later.

Citius (CTXR) and Dr. Reddy's (RDY) have a licensing deal for I/ONTAK, which is currently under FDA review for persistent or rare blood cancer recurrent cutaneous T-cell lymphoma (CTXR), with a decision expected by Sept. 28, 2023.

Read: Seeking Alpha contributor Bret Jensen issued a Hold rating on CTXR, noting that the upcoming FDA decision on I/ONTAK is a binary event.

Who cares about E7777???